A Phase Ia Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered CUG252 in Normal Healthy Volunteers

For healthy subject cohorts, Inclusion Criteria: * Non-smoking adult healthy male and female, aged 18 to 65 years (inclusive), at the time of consent with a body mass index (BMI) between 18.0 and 32.0 kg/m2 (inclusive), at Screening. * Healthy as determined by medical history, physical examination, vital signs, clinical laboratory safety tests, ECG, and chest X-ray Exclusion Criteria: * Active bacterial, viral, fungal infection or known inflammatory process, infection or antibiotic treatment * Laboratory test results outside the local reference range and deemed clinically significant * History of chronic medications, immunosuppressant or steroids * History of malignant neoplasm * History of relevant atopy * History of hypersensitivity to biologic agents or any of the excipients in the formulation. * Excessive xanthine consumption * History of drug or alcohol addiction or dependence within 1 year * Positive of a tuberculosis test or a history of tuberculosis * Abnormal blood pressure and/or ECG parameters * Any prescribed medications within 28 days or nonprescription drugs within 7 days * Previously received aldesleukin or any other IL-2 derivative